U.K. advocacy groups threaten court action over a key provision in the pharma trade deal with the U.S. At issue is the degree to which the government can alter cost-effectiveness outcomes for medicines

https://www.statnews.com/2026/05/17/uk-advocates-threaten-court-action-over-pharma-trade-deal-with-us/?utm_campaign=the_readout&utm_medium=email&_hsenc=p2ANqtz--F7kzNkllPWhud-3bFnPKtyfPYhrujH2aPr9FJ2yoLPxLAnqmRbF8Nfp2MvHzg2k9oBsdF3WEw74nJ6BOfyimffQb9BA&_hsmi=419253004&utm_content=419253004&utm_source=hs_email By Ed SilvermanMay 17, 2026 Pharmalot Columnist, Senior Writer U.K. drug deal sparks legal threat from advocates Two advocacy groups are threatening legal action against the U.K. government over a new drug trade agreement with the U.S. They’re arguing that the deal could undermine the independence of the country’s drug-pricing watchdog and dramatically increase NHS spending on medicines. The agreement, finalized last month, gives the U.K. tariff-free access to the U.S. pharmaceutical market in exchange for a series of industry-friendly concessions, STAT’s Ed Silverman writes. This includes higher NHS drug spending targets, a 25% increase in medicine prices paid by the health system, and changes to how the National Institute for Health and Care Excellence evaluates cost-effectiveness. “The government caved in to threats from Donald Trump and the pharmaceutical industry and signed a deal that experts say could cost the lives of over 300,000 NHS patients,” one advocacy group leader said. "But we believe the process they have followed is unlawful, and we are ready to take them to court to defend NHS patients and our democracy.”